Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS
Authors:
Open Access
- 31 December 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0316573
Abstract
Nirmatrelvir/Ritonavir, acting as an effective agent against COVID-19, has achieved considerable results in clinical studies in terms of drug efficacy. However, there is little research about its medication safety. Based on the FDA adverse event reporting system (FAERS) database, this study aims to mine the adverse reaction signals of the latest major recommended drug Nirmatrelvir/Ritonavir for the antiviral treatment of COVID-19, so as to provide a basis for safe and rational drug use. The reporting odds ratio (ROR) was used to explore the adverse event report data of all COVID-19 emergency use authorization (EUA) products in the FAERS database with the deadline of third quarter of 2023. In the analysis, 135427 adverse drug event (ADE) reports were found, and 35250 ADEs were reported with Nirmatrelvir/Ritonavir as the primary suspected drug, which was involved in multiple system. There was a high signal intensity of dysgeusia (ROR = 72.98), diarrhea (ROR = 3.03) and headache (ROR = 1.25), which was compatible with the adverse reactions recorded in the manual for Nirmatrelvir/Ritonavir. In addition, it was suggested that Nirmatrelvir/Ritonavir might cause pale-colored stools (ROR = 45.53), chromaturia (ROR = 3.07), yellow skin (ROR = 3.62), tongue coating (ROR = 35.55) and other new adverse reactions (not included in the instructions manual for Nirmatrelvir/Ritonavir). The ADEs of Nirmatrelvir/Ritonavir that are not in the instructions and are highly relevant in the real world are supplemented, prompting clinical attention to the ADEs of the drug, and providing a theoretical basis for the safe and effective application of the drug.Keywords
Funding Information
- Natural Science Foundation of Hunan Province (No.2022JJ80036)
- Scientific research project of Hunan Health Commission (No.20200202)
- Clinical pharmacy research project of Hunan Medical Association (No.HMA202001006)
This publication has 27 references indexed in Scilit:
- Extrapulmonary manifestations of COVID-19Nature Medicine, 2020
- Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidenceEuropean Archives of Oto-Rhino-Laryngology, 2020
- Olfactory and Oral Manifestations of COVID‐19: Sex‐Related Symptoms—A Potential Pathway to Early DiagnosisOtolaryngology–Head and Neck Surgery, 2020
- Incidence of Adverse Drug Reactions in COVID‐19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance SystemClinical Pharmacology & Therapeutics, 2020
- Cell entry mechanisms of SARS-CoV-2Proceedings of the National Academy of Sciences, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Case report of familial COVID-19 cluster associated with High prevalence of anosmia, ageusia, and gastrointestinal symptomsIDCases, 2020
- A curated and standardized adverse drug event resource to accelerate drug safety researchScientific Data, 2016
- Profiling Cumulative Proportional Reporting Ratios of Drug-Induced Liver Injury in the FDA Adverse Event Reporting System (FAERS) DatabaseDrug Safety, 2013
- Novel Statistical Tools for Monitoring the Safety of Marketed DrugsClinical Pharmacology & Therapeutics, 2007